In preparing for the July 2010 meeting of the Endocrinologic and Metabolic Drugs AdvisoryCommitteeand the DrugSafetyandRiskManagementAdvisoryCommittee, the FDA sought to provide the committee members with all available data relevant to the cardiovascular safety of rosiglitazone.
Concerned about the entire class of COX-2 inhibitors, the FDA convened a joint session of their Arthritis AdvisoryCommitteeand the DrugSafetyandRiskManagementAdvisoryCommittee on February 16, 17 and 18 to advise the FDA on the risk-benefit profile for these drugs.